Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of EDP1867 in Healthy Volunteers and Inflammatory Diseases
NCT04927195Phase 1Completed
- Sponsor
- Evelo Biosciences
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDP1867 in atopic dermatitis (AD), psoriasis and asthma, sponsored by Evelo Biosciences. Primary endpoints: Adverse Events, Laboratory Measurements and 2 more. Started Feb 2021; status: completed.
02
Drugs
EDP1867
03
Conditions
atopic dermatitis (AD)psoriasisasthma
Beyond the preview
Go deeper on NCT04927195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927195.